North Carolina Pharmaceutical Marketing Department Held Mid-Year Summary Meeting
Release time:
2020-07-22
North Carolina Pharmaceutical Marketing Department Held Mid-Year Summary Meeting
News 7# July 12 , Shanghai North Carolina Pharmaceutical Technology Co., Ltd. Marketing Department Held 2019 Mid-Year Summary Meeting.
The heads of the sales department, project management department and purchasing department under the marketing department respectively reviewed their respective work in the first half of the year. The sales successfully completed the task. The project task execution exceeded the annual quantity of 2018 . The procurement was fully rolled out to ensure the stable operation of the project and production. 4 colleagues from the marketing department and the finance department shared their experiences in four aspects: financial knowledge, sales and communication skills, common sense of experimental mapping and closed-loop management of work.
Li Qian, deputy general manager of North Carolina Pharmaceuticals, affirmed the work in the first half of the year and put forward the core idea of the marketing department in the second half of the year: customer-centered. She stressed that the market needs to go out more, not by low prices but by high-quality quality and service, accurate positioning in the product quality system, more focus on the market in product selection, and solve their pain points around customers. At the same time, she asked the entire marketing team to have the awareness of proposing new projects with the help of market dynamics. At the
meeting, all participants also discussed the sales methods of different products, market judgment, customer requirements for standardization, improvement of quality system, adjustment of sales strategy, and trade-offs between products and channels at this stage. Kang Litao, general manager of North Carolina Pharmaceutical, answered the questions and suggestions raised by everyone. At the same time, he introduced the key points of the future development of North Carolina Pharmaceutical, including the planning of market work in the second half of the year and the support to be given. I hope everyone can unify their thinking and recognize the positioning. At the same time, he said that the goal of North Carolina Medicine is to create high-quality products, which should be the best in the industry and become popular varieties. Be a strategic customer and further develop strategic partners. Before the
meeting, North Carolina Pharmaceutical and his party also visited the Industrial Technology Research Park of the Yangtze River Delta Green Pharmaceutical Collaborative Innovation Center in Deqing. The research park has set up research and development platforms in various directions, such as the Green Pharmaceutical Research Institute, the Pharmaceutical Equipment Research Institute, and the Environmentally Friendly (Three Waste Treatment) Research Institute, which is committed to promoting the transformation and upgrading of the green pharmaceutical industry in the Yangtze River Delta and even the whole country. General Manager Kang Litao and Deputy General Manager Li Qian exchanged and shared with the person in charge of the research institute on the projects currently under development. (Li Yimin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page